Reactivation of Pulmonary Tuberculosis in a Patient With Rheumatoid Arthritis During Treatment With IL-1 Receptor Antagonists (Anakinra)
- 1 August 2007
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in JCR: Journal of Clinical Rheumatology
- Vol. 13 (4), 219-220
- https://doi.org/10.1097/rhu.0b013e31812e00a1
Abstract
This single case report describes reactivation of previous pulmonary tuberculosis (TBC) after 23 months of treatment with the IL-1 receptor antagonist anakinra. This patient had severe acute rheumatoid arthritis (Disease Activity Score >6). Initially, he received treatment with 10 mg prednisolone daily along with oral methotrexate 15 mg weekly. Methotrexate was discontinued after 3 months because of repeated liver enzyme elevation. After the disease became more active, he was treated with the IL-1 receptor antagonist along with 10 mg prednisolone daily. One month later, the patient improved significantly, and prednisolone was decreased to 5 mg on alternate days and discontinued after another 3 months. After 23 months of anakinra monotherapy, the patient developed pulmonary TBC and was put on quadruple anti-TBC treatment, which resulted in excellent recovery. Six years before, the patient had pulmonary TBC and received triple anti-TBC treatment for 9 months with complete clinical and radiologic remission. We believe this is the first reported case of TBC reactivation during anakinra treatment.Keywords
This publication has 6 references indexed in Scilit:
- Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factorAnnals Of The Rheumatic Diseases, 2005
- Updated consensus statement on biological agents, specifically tumour necrosis factor (TNF ) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Annals Of The Rheumatic Diseases, 2005
- British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-α treatmentsRheumatology, 2005
- Tumor Necrosis Factor and Its Blockade in Granulomatous Infections: Differential Modes of Action of Infliximab and Etanercept?Clinical Infectious Diseases, 2005
- Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseasesAutoimmunity Reviews, 2005
- TNF-blocking agents and tuberculosis: new drugs illuminate an old topicRheumatology, 2005